Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulka Vaishampayan

Showing results (131-140 of 176) with videos related to

Pageof 18
Sort By:
Frontiers in Oncology|May 8, 2026
Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumorsAntoine Italiano, Teresa García Manrique, Enrique Grande Pulido, et al.
Cancer|March 26, 2020
Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA resultsSumanta K Pal, Dean Bajorin, Nazli Dizman, et al.
Oncology|April 20, 2023
Radiogenomic Associations Clear Cell Renal Cell Carcinoma: An Exploratory StudyDerek H Liu, Komal A Dani, Sharath S Reddy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2026
Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA Targeted Tubulysin Conjugate EC1169Samir Zaidi, Phillip H Kuo, Tiago Paiva Prudente, et al.
Nutrients|June 19, 2024
Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic TherapyHedyeh Ebrahimi, Dena Battle, Nicholas J Salgia, et al.
Nature Medicine|January 13, 2026
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trialTimothy A Yap, Randy F Sweis, Ulka Vaishampayan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2021
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 StudySumanta K Pal, Bradley McGregor, Cristina Suárez, et al.
The American Journal of Surgical Pathology|November 23, 2023
Hybrid Oncocytic Tumors (HOTs) in Birt-Hogg-Dubé Syndrome Patients-A Tale of Two Cities: Sequencing Analysis Reveals Dual Lineage Markers Capturing the 2 Cellular Populations of HOTXiao-Ming Wang, Rahul Mannan, Yuping Zhang, et al.
European Urology Oncology|December 2, 2019
Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint InhibitorsJeffrey Graham, Amishi Y Shah, J Connor Wells, et al.
Lancet (London, England)|February 16, 2021
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trialSumanta K Pal, Catherine Tangen, Ian M Thompson, et al.
Pageof 18

Showing results (131-140 of 176) with videos related to

Sort By:
Pageof 18
Frontiers in Oncology|May 8, 2026
Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumorsAntoine Italiano, Teresa García Manrique, Enrique Grande Pulido, et al.
Cancer|March 26, 2020
Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA resultsSumanta K Pal, Dean Bajorin, Nazli Dizman, et al.
Oncology|April 20, 2023
Radiogenomic Associations Clear Cell Renal Cell Carcinoma: An Exploratory StudyDerek H Liu, Komal A Dani, Sharath S Reddy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2026
Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA Targeted Tubulysin Conjugate EC1169Samir Zaidi, Phillip H Kuo, Tiago Paiva Prudente, et al.
Nutrients|June 19, 2024
Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic TherapyHedyeh Ebrahimi, Dena Battle, Nicholas J Salgia, et al.
Nature Medicine|January 13, 2026
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trialTimothy A Yap, Randy F Sweis, Ulka Vaishampayan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2021
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 StudySumanta K Pal, Bradley McGregor, Cristina Suárez, et al.
The American Journal of Surgical Pathology|November 23, 2023
Hybrid Oncocytic Tumors (HOTs) in Birt-Hogg-Dubé Syndrome Patients-A Tale of Two Cities: Sequencing Analysis Reveals Dual Lineage Markers Capturing the 2 Cellular Populations of HOTXiao-Ming Wang, Rahul Mannan, Yuping Zhang, et al.
European Urology Oncology|December 2, 2019
Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint InhibitorsJeffrey Graham, Amishi Y Shah, J Connor Wells, et al.
Lancet (London, England)|February 16, 2021
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trialSumanta K Pal, Catherine Tangen, Ian M Thompson, et al.
Pageof 18